• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Pharma industry news

Gilead Sciences logo

Gilead announces SVR12 rates from Phase 3 study evaluating Harvoni® for the treatment of chronic hepatitis C in patients co-infected with HIV

Posted on: 27 February 2015 | Source: Gilead Sciences

96 percent SVR12 rate for hepatitis C genotypes 1 and 4 among HIV-infected patients on antiretroviral therapy...

Gilead logo

Gilead announces Phase 3 results for investigational once-daily single tablet HIV regimen containing tenofovir alafenamide (TAF)

Posted on: 27 February 2015 | Source: Gilead Sciences

First TAF-based regimen found to be non-inferior with improved renal and bone parameters compared to stribild®...

Novartis

Novartis lung cancer drug Zykadia® recommended for EU approval in patients with ALK+ NSCLC previously treated with crizotinib

Posted on: 27 February 2015 | Source: Novartis

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion for Zykadia® (ceritinib) to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib...

Moberg Pharma

Moberg Pharma AB (Publ) year-end report 2014

Posted on: 27 February 2015 | Source: Moberg Pharma

Successful fourth quarter and the first profitable full year...

UCB Logo

UCB Full Year Report 2014: Core medicines grow by 24% while next wave of new potential solutions for patients advances

Posted on: 27 February 2015 | Source: UCB

"UCB continues its growth path with Cimzia®, Vimpat® and Neupro®, now accounting for 50% of our net sales. We continue to advance and prepare the launches of our next wave of potential new patient solutions: brivaracetam, epratuzumab and romosozumab..."

Bristol Myers Squibb logo

ALLY trial demonstrates 97% hepatitis C cure rates among patients coinfected with HIV after ribavirin-free investigational 12-week regimen of daclatasvir and sofosbuvir

Posted on: 27 February 2015 | Source: Bristol-Myers Squibb Company

Bristol-Myers Squibb Company announced results from ALLY-2, a Phase III clinical trial evaluating the investigational once-daily combination of daclatasvir and sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) coinfected with HIV – a patient population that historically has been challenging to treat in large part due to potential drug-drug interactions between the therapy regimens used to treat each infection...

GlobalData

Japanese pharmaceutical market value edging towards $80 billion by 2020, says GlobalData

Posted on: 27 February 2015 | Source: GlobalData

Japan’s pharmaceutical market value is set to grow at a tepid Compound Annual Growth Rate (CAGR) of 1.3% from $72.8 billion in 2013 to reach $79.8 billion by 2020, driven by new product launches and the healthcare burden of the country’s aging population, according to research and consulting firm GlobalData...

Johnson & Johnson

Johnson & Johnson tops IDEA Pharma’s Productive Innovation Index for the third consecutive year

Posted on: 27 February 2015 | Source: IDEA Pharma

Now in its fifth year, the Productive Innovation Index (PII) celebrates the top 30 pharmaceutical companies most effective at developing and commercialising new medicines – bringing innovations to market successfully...

gaffi

Fungal disease deaths – just “$30 a person” for major reductions in AIDS globally

Posted on: 26 February 2015 | Source: GAFFI

Early detection and treatment of fungal meningitis and pneumonia can save hundreds of thousands of lives, for a cost of 'only $30' per HIV patient, the world's first stakeholder meeting on fungal diseases hosted by GAFFI (Global Action Fund for Fungal Infections) and held in Seattle, USA has concluded...

Bristol Myers Squibb logo

48-week analysis of investigational HIV-1 attachment inhibitor paves way for Phase III trial initiation

Posted on: 26 February 2015 | Source: Bristol-Myers Squibb Company

Bristol-Myers Squibb Company announced data from a Phase IIb trial of investigational compound BMS-663068, designed as an HIV-1 attachment inhibitor, in treatment-experienced HIV-1 patients...

GlobalData

Global atrial fibrillation treatment market to peak at $9.4 Billion in 2020, says GlobalData

Posted on: 26 February 2015 | Source: GlobalData

The global market for atrial fibrillation (AF) treatment will more than double in value from $4.6 billion in 2013 to peak sales of $9.4 billion in 2020, before declining to $5.7 billion by 2023 as new oral anticoagulants (NOACs) become genericized, according to research and consulting firm GlobalData...

Insulin pen

Sanofi receives FDA approval of once-daily basal insulin Toujeo®

Posted on: 26 February 2015 | Source: Sanofi

The U.S. Food and Drug Administration (FDA) has approved Sanofi's Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes...